We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 26, 2019

Neoadjuvant FOLFIRINOX and IMRT Concurrent With FDR Gemcitabine in Borderline Resectable Pancreatic Cancer

International Journal of Radiation Oncology, Biology, Physics

 

Additional Info

Disclosure statements are available on the authors' profiles:

International Journal of Radiation Oncology, Biology, Physics
Phase II Trial of Neoadjuvant FOLFIRINOX and IMRT Concurrent With FDR-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer
Int. J. Radiat. Oncol. Biol. Phys 2019 Sep 05;[EPub Ahead of Print], NH Tran, V Sahai, KA Griffith, H Nathan, R Kaza, KC Cuneo, J Shi, E Kim, CJ Sonnenday, CS Cho, TS Lawrence, MM Zalupski

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading